Jump to content

New Oxymetazoline Cream 1% (Rhofade)


Recommended Posts

  • Root Admin

Allergan announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for oxymetazoline HCl cream 1%  (Rhofade) for the treatment of persistent facial erythema associated with rosacea in adults. MPR

Should be released sometime in 2017. 

The name Rhofade is mentioned in this article

Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results – Earnings Call Transcript

A document prepared for Allergan’s November 4, 2015 R&D Day presentation is available to download which is primarily about this new Oxymetazoline 1% Cream which may be released next year. David Pascoe has some insightful comments about this document worth reading. 

FDA has approved Rhofade.

Link to comment
Share on other sites

  • 4 weeks later...

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...